ReviewPLoS pathogens2022

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.

Daniel Clark Files et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.